Perflurooctanoic acid induces developmental cardiotoxicity in chicken embryos and hatchlings

Toxicology

Volumn 293, Issue 1-3, 2012, Pages 97-106

  Jiang, Qixiao ^a   Lust, Robert M ^a   Strynar, Mark J ^b   Dagnino, Sonia ^b   DeWitt, Jamie C ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Cardiac myofibril ATPase; Cardiac ultrasound; Chicken embryo; Immunohistochemistry; Perflurooctanoic acid

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM; MYOSIN; PERFLUOROOCTANOIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CHICKEN; CONTROLLED STUDY; DRUG EXPOSURE; ECHOCARDIOGRAPHY; EMBRYO; ENZYME ACTIVITY; ENZYME ASSAY; HATCHLING; HEART DEVELOPMENT; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART LEFT VENTRICLE WALL; HEART RATE; HEART RIGHT VENTRICLE; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MUSCLE FIBRIL; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANIMALS; AVIAN PROTEINS; CAPRYLATES; CARDIAC MYOSINS; CARDIOTOXINS; CHICK EMBRYO; CHICKENS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; ENVIRONMENTAL POLLUTANTS; FLUOROCARBONS; HEART; HEART RATE; HEART VENTRICLES; IMMUNOHISTOCHEMISTRY; MYOCARDIUM; MYOFIBRILS; ORGAN SIZE; ORGANOGENESIS; STROKE VOLUME;

AVES; GALLUS GALLUS; MAMMALIA;

EID: 84857049213     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.01.005     Document Type: Article

References (51)

1. Apelberg B.J., Goldman L.R., Calafat A.M., Herbstman J.B., Kuklenyik Z., Heidler J., Needham L.L., Halden R.U., Witter F.R. Determinants of fetal exposure to polyfluoroalkyl compounds in Baltimore, Maryland. Environ. Sci. Technol. 2007, 11:3891-3897.
2. Beaufort-Krol G.C., Schasfoort-van Leeuwen M.J., Stienstra Y., Bink-Boelkens M.T. Longitudinal echocardiographic follow-up in children with congenital complete atrioventricular block. Pacing Clin. Electrophysiol. 2007, 30:1339-1343.
3. Biegel L.B., Hurtt M.E., Frame S.R., O'Connor J.C., Cook J.C. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol. Sci. 2001, 60:44-55.
4. Bossi R., Riget F.F., Dietz R., Sonne C., Fauser P., Dam M., Vorkamp K. Preliminary screening of perfluorooctane sulfonate (PFOS) and other fluorochemicals in fish, birds and marine mammals from Greenland and the Faroe Islands. Environ. Pollut. 2005, 136:323-329.
5. Buchhorn R., Hulpke-Wette M., Ruschewski W., Ross R.D., Fielitz J., Pregla R., Hetzer R., Regitz-Zagrosek V. Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease. Cardiol. Young 2003, 13:36-43.
6. Candau R., Iorga B., Travers F., Barman T., Lionne C. At physiological temperatures the ATPase rates of shortening soleus and psoas myofibrils are similar. Biophys. J. 2003, 85:3132-3141.
7. Cappelli V., Moggio R., Monti E., Paracchini L., Piccinini F., Reggiani C. Reduction of myofibrillar ATPase activity and isomyosin shift in delayed doxorubicin cardiotoxicity. J. Mol. Cell Cardiol. 1989, 21:93-101.
8. CDC (Centers for Disease Control and Prevention), 2011. National Report on Human Exposure to Environmental Chemicals. Serum Perfluorooctanoic Acid (PFOA). Available from: (accessed 03.08.11). http://www.cdc.gov/exposurereport/data_tables/LBXPFOA_DataTables.html.
9. Chang A.N., Harada K., Ackerman M.J., Potter J.D. Functional consequences of hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin. J. Biol. Chem. 2005, 280:34343-34349.
10. DeWitt J.C., Copeland C.B., Strynar M.J., Luebke R.W. Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ. Health Perspect. 2008, 116:644-650.
11. DeWitt J.C., Copeland C.B., Luebke R.W. Suppression of humoral immunity by perfluorooctanoic acid is independent of elevated serum corticosterone concentration in mice. Toxicol. Sci. 2009, 109:106-112.
12. DeWitt J.C., Shnyra A., Badr M.Z., Loveless S.E., Hoban D., Frame S.R., Cunard R., Anderson S.E., Meade B.J., Peden-Adams M.M., Luebke R.W., Luster M.I. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit. Rev. Toxicol. 2009, 39:76-94.
13. Dukanović N., Jakovljević V., Mujović V.M. Evaluation of myocardial relaxation in conditions of cardiac remodeling. Med. Pregl. 2009, 62:555-568.
14. DuPont, 2011. Information on PFOA. Available from: (accessed 03.08.11). http://www2.dupont.com/PFOA2/en_US/index.html.
15. Eriksson J.G. Early growth, and coronary heart disease and type 2 diabetes: experiences from the Helsinki Birth Cohort Studies. Int. J. Obes. (Lond.) 2006, 30(Supply 4):S18-S22.
16. Falandysz J., Taniyasu S., Yamashita N., Rostkowski P., Zalewski K., Kannan K. Perfluorinated compounds in some terrestrial and aquatic wildlife species from Poland. J. Environ. Sci. Health A 2007, 42:715-719.
17. Grimes A.C., Erwin K.N., Stadt H.A., Hunter G.L., Gefroh H.A., Tsai H.J., Kirby M.L. PCB126 exposure disrupts zebrafish ventricular and branchial but not early neural crest development. Toxicol. Sci. 2008, 106:193-205.
18. Henshel D.S., DeWitt J., Troutman A. Using chicken embryos for teratology studies. Curr. Protoc. Toxicol. 2003, 1-19. (Chapter 13: Unit 13.4).
19. Hoffman K., Webster T.F., Bartell S.M., Weisskopf M.G., Fletcher T., Vieira V.M. Private drinking water wells as a source of exposure to perfluorooctanoic acid (PFOA) in communities surrounding a fluoropolymer production facility. Environ. Health Perspect. 2011, 119:92-97.
20. Izumi M., Fujio Y., Kunisada K., Negoro S., Tone E., Funamoto M., Osugi T., Oshima Y., Nakaoka Y., Kishimoto T., Yamauchi-Takihara K., Hirota H. Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathway. J. Biol. Chem. 2001, 276:31133-31141.
21. Kannan K., Corsolini S., Falandysz J., Fillmann G., Kumar K.S., Loganathan B.G., Mohd M.A., Olivero J., Van Wouwe N., Yang J.H., Aldoust K.M. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ. Sci. Technol. 2004, 38:4489-4495.
22. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 1991, 114:345-352.
23. Langley-Evans S.C. Developmental programming of health and disease. Proc. Nutr. Soc. 2006, 65:97-105.
24. Lau C., Butenhoff J.L., Rogers J.M. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol. Appl. Pharmacol. 2004, 198:231-241.
25. Lionne C., Iorga B., Candau R., Travers F. Why choose myofibrils to study muscle myosin ATPase. J. Muscle Res. Cell Motil. 2003, 24:139-148.
26. Liu C.J., Cheng Y.C., Lee K.W., Hsu H.H., Chu C.H., Tsai F.J., Tsai C.H., Chu C.Y., Liu J.Y., Kuo W.W., Huang C.Y. Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells. Mol. Cell. Biochem. 2008, 313:167-178.
27. Lutin W.A., Brumund M.R., Jones C., Tharpe C.E., Montegomery M., McCaffrey F.M. Hemodynamic abnormalities in fetuses with congenital heart disease. Pediatr. Cardiol. 1999, 20:390-395.
28. Martin J.W., Whittle D.M., Muir D.C., Mabury S.A. Perfluoroalkyl contaminants in a food web from Lake Ontario. Environ. Sci. Technol. 2004, 38:5379-5385.
29. Nolan L.A., Nolan J.M., Shofer F.S., Rodway N.V., Emmett E.A. The relationship between birth weight, gestational age, and perfluorooctanoic acid (PFOA)-contaminated public drinking water. Reprod. Toxicol. 2009, 27:231-238.
30. Nolan L.A., Nolan J.M., Shofer F.S., Rodway N.V., Emmett E.A. Congenital anomalies, labor/delivery complications, maternal risk factors and their relationship with perfluorooctanoic acid (PFOA)-contaminated public drinking water. Reprod. Toxicol. 2010, 29:147-155.
31. O'Brien J.M., Crump D., Mundy L.J., Chu S., McLaren K.K., Vongphachan V., Letcher R.J., Kennedy S.W. Pipping success and liver mRNA expression in chicken embryos exposed in ovo to C8 and C11 perfluorinated carboxylic acids and C10 perfluorinated sulfonate. Toxicol. Lett. 2009, 190:134-139.
32. Olivotto I., Girolami F., Nistri S., Rossi A., Rega L., Garbini F., Grifoni C., Cecchi F., Yacoub M.H. The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice. J. Cardiovasc. Transl. Res. 2009, 2:349-367.
33. Olsen G.W., Gilliland F.D., Burlew M.M., Burris J.M., Mandel J.S., Mandel J.H. An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J. Occup. Environ. Med. 1998, 40:614-622.
34. Olsen G.W., Church T.R., Miller J.P., Burris J.M., Hansen K.J., Lundberg J.K., Armitage J.B., Herron R.M., Medhdizadehkashi Z., Nobiletti J.B., O'Neill E.M., Mandel J.H., Zobel L.R. Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ. Health Perspect. 2003, 111:1892-1901.
35. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., Zobel L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 2007, 115:1298-1305.
36. Olsen G.W., Ellefson M.E., Mair D.C., Church T.R., Goldberg C.L., Herron R.M., Medhdizadehkashi Z., Nobiletti J.B., Rios J.A., Reagen W.K., Zobel L.R. Analysis of a homologous series of perfluorocarboxylates from american red cross adult blood donors, 2000-2001 and 2006. Environ. Sci. Technol. 2011, 45:8022-8029.
37. Peters J.M., Cheung C., Gonzalez F.J. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand. J. Mol. Med. 2005, 83:774-785.
38. Reiner J.L., Nakayama S.F., Delinsky A.D., Stanko J.P., Fenton S.E., Lindstrom A.B., Strynar M.J. Analysis of PFOA in dosed CD1 mice. Part 1. Methods development for the analysis of tissues and fluids from pregnant and lactating mice and their pups. Reprod. Toxicol. 2009, 27:360-364.
39. Shi Y., Moon M., Dawood S., McManus B., Liu P.P. Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011, 36:296-305.
40. Steenland K., Jin C., MacNeil J., Lally C., Ducatman A., Vieira V., Fletcher T. Predictors of PFOA levels in a community surrounding a chemical plant. Environ. Health Perspect. 2009, 117:1083-1088.
41. Steenland K., Fletcher T., Savitz D.A. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ. Health Perspect. 2010, 118:1100-1108.
42. Stein C.R., Savitz D.A., Dougan M. Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. Am. J. Epidemiol. 2009, 170:837-846.
43. Steinmetz M., Quentin T., Poppe A., Paul T., Jux C. Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat. Basic Res. Cardiol. 2005, 100:263-269.
44. Takagi Y., Bruyere H.J., Nishikawa T. Protective effect of ouabain on adriamycin-induced cardiovascular anomalies in chick embryos. Teratology 1989, 39:573-580.
45. Takano M., Otsuka F., Matsumoto Y., Inagaki K., Takeda M., Nakamura E., Tsukamoto N., Miyoshi T., Sada K.E., Makino H. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α. Mol. Cell Endocrinol. 2011, 348:224-232.
46. Tsai I.C., Chen M.C., Jan S.L., Wang C.C., Fu Y.C., Lin P.C., Lee T. Neonatal cardiac multidetector row CT: why and how we do it. Pediatr. Radiol. 2008, 38:438-451.
47. USEPA (U.S. Environmental Protection Agency), 2011. 2010/2015 PFOA Stewardship Program. Available from: (accessed 03.08.11). http://www.epa.gov/opptintr/pfoa/pubs/stewardship/.
48. Walker M.K., Catron T.F. Characterization of cardiotoxicity by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related chemicals during early chick embryo development. Toxicol. Appl. Pharmacol. 2000, 167:210-221.
49. Walker M.K., Pollenz R.S., Smith S.M. Expression of the aryl hydrocarbon receptor (AhR) and AhR nuclear translocator during chick cardiogenesis is consistent with 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced heart defects. Toxicol. Appl. Pharmacol. 1997, 143:407-419.
50. Wang N., Szostek B., Buck R.C., Folsom P.W., Sulecki L.M., Capka V., Berti W.R., Gannon J.T. Fluorotelomer alcohol biodegradation-direct evidence that perfluorinated carbon chains breakdown. Environ. Sci. Technol. 2005, 39:7516-7528.
51. Wolf C.J., Fenton S.E., Schmid J.E., Calafat A.M., Kuklenyik Z., Bryant X.A., Thibodeaux J., Das K.P., White S.S., Lau C.S., Abbott B.D. Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicol. Sci. 2007, 95:462-473.